(Q35005589)

5 August 2017

1 reference

title

Lipid lowering: another method of reducing blood pressure? (English)

1 reference

5 August 2017

Wierzbicki AS

1

1 reference

5 August 2017

1 November 2002

1 reference

Journal of Human Hypertension

5 August 2017

1 reference

5 August 2017

16

1 reference

5 August 2017

11

1 reference

5 August 2017

753-760

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001483

5 August 2017

0 references

cites work

Association between blood pressure and serum lipids in a population. The Tromsø Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Coronary risk factors in a community. Findings in Tecumseh, Michigan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Clustering of cardiovascular disease risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

The epidemiology of impaired glucose tolerance and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Hyperlipidaemia, hypertension, and coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

n-3 polyunsaturated fatty acids and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

A prospective study of sodium-lithium countertransport and hypertension in Utah

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Endothelial dysfunction: does it matter? Is it reversible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vasc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Aortic pulse wave velocity as a marker of cardiovascular disease in subjects over 70 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Cardiovascular protection and blood pressure reduction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Prospective Analysis of Traits Related to 6-Year Change in Sodium-Lithium Countertransport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

Controversies surrounding erythrocyte sodium-lithium countertransport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Sodium-lithium countertransport in erythrocytes of hypertension prone families in Utah

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Sodium-lithium countertransport activity is linked to chromosome 5 in baboons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Association and linkage analysis of alpha-adducin polymorphism: is the glass half full or half empty?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Hyperlipidaemia, hypertension; and coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

A controlled trial of plasma lipid reduction in peripheral atherosclerosis--an interim report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Pravastatin affects blood pressure and vascular reactivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001483

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001483

1 reference

PubMed ID

12444536

Dimensions Publication ID

5 August 2017

0 references

1 reference

PubMed ID

12444536